Supplementary materials: Healthcare costs and resource utilization of patients with chronic post-traumatic stress disorder: a retrospective US claims analysis of commercially insured patients

These are peer-reviewed supplementary materials for the article 'Healthcare costs and resource utilization of patients with chronic post-traumatic stress disorder: a retrospective US claims analysis of commercially insured patients' published in the Journal of Comparative Effectiveness Research.

• Table A1: ICD-10-CM codes for chronic PTSD
• Table A2: ICD-10 CM codes for acute PTSD
• Table A3: ICD-10-CM codes related to cancer diagnosis
• Table A4: ICD-10-CM codes related to MDD, bipolar disorder, and schizophrenia
• Table A5: NDC codes related to FDA-approved medications for PTSD treatment
• Table A6: Procedure codes related to the psychotherapies used for PTSD management
• Table A7: ICD-10-CM codes related to anxiety
• Table A8: Demographic characteristics of the matched population
• Table A9: Clinical characteristics of the matched population
• Table A10: Out-of-pocket healthcare costs of PTSD patients during the 2-year follow-up period within the matched population
• Table A11: Overall healthcare costs of PTSD patients during the 2-year follow-up period within the matched population
• Table A12: The resource use of PTSD patients during the first year of the follow-up period within the matched population
• Table A13: Demographic characteristics of PTSD patients with SUD/AUD diagnosis
• Table A14: Clinical characteristics of PTSD patients with SUD/AUD diagnosis
• Table A15: Out-of-pocket healthcare costs of PTSD during the 2-year follow-up period within the sub-sample of patients diagnosed with SUD/AUD
• Table A16: Overall healthcare costs of PTSD during the 2-year follow-up period within the sub-sample of patients diagnosed with SUD/AUD
• Table A17: Resource use during the first year of the follow-up period within the sub-sample of chronic PTSD patients diagnosed with SUD/AUD

Aim: Exploring the healthcare costs and resource use among privately insured US patients with posttraumatic stress disorder (PTSD). Methods: This study used Merative MarketScan data. The index date was defined as the first PTSD claim. Study period included a 1-year pre-index and 2-year post-index follow-up. Cases with only acute PTSD, cancer, or insurance gap during the study period were excluded. The PTSD with (PwC) and PTSD without comorbidities (PwoC) cohorts were defined by the presence/absence of comorbid mental health conditions (schizophrenia, bipolar and major depressive disorder). Baseline PTSD (BP) cohort included PwoC cases with only index PTSD event and without FDA-approved PTSDmedications or psychotherapy. Sub-analysis is conducted among patients with PTSD and substance/alcohol use disorder. Study cohorts were matched in a 1:1:1 ratio. Results: The matched sample included 5076 patients (1681 PwC, 1681 PwoC, 1714 BP). PwC patients had higher 2-year PTSD-related costs than PwoC and BP patients ($3762 vs $1750 and $841; all p < 0.001). The same trend was noted among all-cause and anxiety-related costs. PwC patients had higher 2-year PTSD-related inpatient and emergency department (ED) rates than PwoC (10.2% vs 1.7% and 6.8% vs 2.6%, all p < 0.001) and inpatient and outpatient rates than BP (10.2% vs 2.1% and 98.0% vs 93.1%; all p ≤ 0.004). The sub-analysis had 3776 patients (3154 PwC, 537 PwoC, 85 BP). PwC had higher 2-year PTSD-related costs than PwoC and BP ($7668 vs $2919 and $1,483; all p < 0.001). The same trend was noted in all-cause and anxiety-related costs. PwC also had higher 2-year PTSD-related inpatient and ED rates than PwoC (25.6% vs 10.4% and 12.7% vs 5.2%; all p < 0.001) and inpatient and outpatient rates than BP (25.6% vs 8.2% and 95.5% vs 84.7%; all p < 0.001). Conclusion: PTSD is associated with high healthcare costs and resource use. The highest economic burden was observed in patients with PTSD and mental health comorbidities.